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REVIEW ARTICLE

The Beneﬁcial Effects of Ferula asafoetida Oleo-gum
Resin in Gastrointestinal Disorders
Mohaddese Mahboubi
Medicinal Plants Research Department, Research and Development, TabibDaru Pharmaceutical Company, Kashan, Iran

Abstract
Ferula asafoetida is a plant from Umbelliferae Family, which its gum is traditionally used to treat the gastrointestinal
disorders (parasite, bloating, digestion, cancer). According to its traditional applications, the subject of this review was to
evaluate the efﬁcacy of F. asafoetida in management of different gastrointestinal disorders in modern medicine. For this
purpose, the scientiﬁc resources (PubMed, Web of Science, Scopus, Google Scholar, SpringerLink, SciFinder, ACS
Publications, and Wiley), traditional books, and thesis were investigated by the word of F. asafoetida, Hing, and
gastrointestinal tract and the results were evaluated. There was one clinical trial on the efﬁcacy of F. asafoetida in
treatment of functional dyspepsia, and the other pharmacological activities such as anti-parasite, anti-cancer, antidiarrhea and liver protective effects were evaluated in preclinical studies. Although, F. asafoetida can be proposed as a
good candidate for treatment of gastrointestinal disorders, but the majority of studies have been limited to the experimental investigations. Therefore, evaluation of its efﬁcacy and safety in well-designed human clinical studies is
required to use of this valuable oleo-gum resin.
Keywords: Ferula asafoetida, Gum, Gastrointestinal diseases, Hing, Fetid

1. Introduction

F

erula asafoetida L. (Umbelliferae Family) with
distinctive fetid smell is native to mountains of Iran,
Pakistan, and Afghanistan and it is usually exported
from Iran to other parts of the world, especially to India.
The English common name of asafoetida is the “Food of
the Gods”, or “Devils dung”.
Asafoetida is a two syllabubs Latin word (Assafoetida) with the means of stinky gum [1]. Oleo-gum
resin of F. asafoetida is extracted from its root and
contains the essential oil (6e17%), resin (40e64%),
and gum (20e25%) [2]. Yellowish-white to reddish
brown color asafoetida gum has intense alliaceous
penetrating odor; and bitter, alliaceous and acrid
taste. Carbohydrates (67.8%), moisture (16%), protein (4%), fat (1.1%), minerals (7.0%) and ﬁbers
(4.1%) are present in asafoetida gum [3]. Umbelliferone (7-hydroxycoumarin), karatavicinol, umbelliprenin, farnesiferol B, and farnesiferol C are
extracted from F. asafoetida gum [4]. The yield of

resin and its chemical proﬁle inﬂuences by different
factors including the climatic, genetic and edaphic
factors. There is a positive correlation between
precipitation rate and the yield of resin from the
roots. The high temperature (low altitude and precipitation rate) increases progressively the essential
oil's yields [5]. The main industrial compound from
asafetida is its oleo-gum resin, which it is rich in
essential oil [6]. (E)-b-ocimene, n-propyl sec-butyl
disulﬁde, (Z)-propenyl sec-butyl disulﬁde, (E)-propenyl sec-butyldisulﬁde, a-pinene, and b-pinene
are the main components of asafoetida essential oil
[7] (Fig. 1).
Asafoetida gum is used as condiment and ﬂavor in
Indian food culture. In Nepal, asafoetida is used as a
part of daily diet [8]. A combination of asafoetida
and pine nuts is used to ﬂavor the foods. Asafoetida
is traditionally used as digestive aid, appetizer, and
for treatment of ﬂatulence, colic, worms (round
worms, pinworms) and other intestinal disorders
[9]. Frying the asafoetida gum in oil or blending with
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Fig. 1. The structure of components in asafetida oleo gum resin.

51

52

BULLETIN OF FACULTY OF PHARMACY, CAIRO UNIVERSITY 2022;59:50e63

ﬂour and maize reduces its harshness [10]. The
same quantity of asafoetida herb with opium was
ingested as opium's antidote. Asafoetida gum is
used as necklace against cold and fevers [11]. Oral
use of asafoetida is prescribed for enhancing the
libido, male fertility and erectile dysfunction in
Greco-Arab Traditional medicine [12]. Intra-vaginal
asafoetida gum is used as contraceptive agent in
Egypt [13]. In India, dried asafoetida gum, with
Brassica alba, and rocky salt in vinegar is taken orally
as abortifacient [14]. In Afghanistan, asafoetida gum
hot water suspension is used for whooping cough,
hysteria, and ulcers [15]. Topical application of
asafoetida paste on chest is used for whooping
cough in Fiji [16].
There are some review articles on biological activities of asafoetida [6,17,18], but there is no review
study for its efﬁcacy in gastrointestinal disorders.
Due to traditional uses of asafoetida in gastrointestinal disorders, and no presence of review on its
efﬁcacy in gastro-intestinal disorders, the aim of this
article was to evaluate the modern literatures on
efﬁcacy of asafoetida in gastrointestinal disorders
according to its traditional claims.

2. Traditional uses of F. asafoetida in
gastrointestinal diseases
Asafoetida is known as anti-colic herb, which
prevents the intestinal spasms and spasmodic pain
[10]. The indication of asafoetida in European
countries is abdomen cancer, liver cancer, cholera,
colic (cramp, ﬂatulence), colitis, constipation, diarrhea, dyspepsia, stomachache, and worm [1].
Asafoetida dried fruit is the ingredient of gruel or
pills for treatment of constipation, indigestion,
dyspepsia, chronic gastritis, and irritable colon in
western countries [19]. Asafoetida is used for colic
pain, indigestion, ﬂatulence, and constipation in
Unani, Arab, and Ayurveda traditional medicines
[20]. Asafoetida gum is used in formulations of
Hingavaadi Bati, Hingu-triguna Taila (Ashtaanga
Hridaya), Habb-e-Hilteet for treatment of colic, loss
of appetite, intestinal colic, ﬂatulence, and chronic
constipation. In India, the combination of asafoetida
with cayenne, pepper and sweet ﬂag is a remedy for
cholera [21]. Asafoetida is known as anti-helminthic
gum, and is used for treatment of ascites, and dysentery in Taiwan [22]. In China, plant decoction is
vermifuge herb [23]. Oral administration of asafoetida dried root is known as vermifuge, analgesic and
antispasmodic agent in Egypt [24]. Oral asafoetida
gum hot water suspension is used for upset stomach

[16]. Asafoetida gum resin is taken orally to prevent
the guinea worm diseases [25]. In Nepal, asafoetida
gum water extract is used for its anti-helminthic
properties [26]. In United States, asafoetida gum
ﬂuid extract is taken orally as anti-helminthic and
powerful antispasmodic agent [27]. In Iranian
traditional medicine, asafoetida is used for treatment of gastrointestinal ailments (spasm, constipation), intestinal parasites, stomach tonic, and
dyspepsia (indigestion, appetite, bloating). Avicenna
used asafoetida for digestion [28]. Due to traditional
uses of asafoetida gum in treatment of gastrointestinal diseases, we evaluated its efﬁcacy in modern
medicines (Tables 1 and 2).
2.1. F. asafoetida and liver functions
Liver is a vital organ for detoxiﬁcation of the body
and the responsible organ for metabolic functions.
The liver protective effects of oral 100 mg/kg
asafoetida aqueous extract against 3 mg/kg sodium
arsenate for 4 weeks in Swiss albino mice against
sodium arsenate reduced the alanine aminotransferase level (ALT) from 210 ± 7.26 U/ml to 108 ± 2.71
and 82.0 ± 1.24 U/ml after 4 and 6 weeks of
asafoetida administration. The aspartate aminotransferase (AST) level reduced from 198 ± 4.78 to
112 ± 1.93 U/ml and 78 ± 1.07 U/ml after 4 and 6
weeks of asafoetida administration. Asafoetida
extract reduced the increased alkaline phosphatase
(ALP) level in arsenic treated mice (24 ± 1.91 KA) to
17 ± 0.85 and 13 ± 0.51 after 4 weeks and 6 weeks.
Bilirubin level reduced from 2.43 ± 0.48 mg/dl to
1.67 ± 0.08 mg/dl and 1.30 ± 0.03 mg/dl after 4 and 6
weeks of treatment with asafoetida [29]. The elevation in ALT, AST, ALP, and bilirubin levels in
presence of arsenic is a feature of abnormal liver
function, which is associated with high incidence of
liver and cardiovascular diseases [30]. Therefore,
oral administration of asafoetida signiﬁcantly
restored the liver enzymes in arsenic exposed animals, which may be caused by the components of
asaresinotannols A, asaresinotannols B, ferulic acid,
and umbelliferone [3].
The liver protective effects of asafoetida aqueous
extract (50, 100, 200 mg/kg) were compared with
1 ml/kg/day Liv-52 against 1 ml/kg carbon tetrachloride (CCL4) for a period of 14 days in albino rats.
The treatment duration was 21 days after inducing
the hepatotoxicity. CCL4 signiﬁcantly increased the
level of ALT, AST, and total bilirubin contents.
Treatment of animals with different concentrations
of asafoetida signiﬁcantly reduced the serum ALT,
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Table 1. The Potency of asafetida in gastrointestinal diseases.
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AST and bilirubin content. The effects of
200 mg/kg asafoetida extract on ALT, AST and
total bilirubin content were higher than the
other doses of F. asafoetida gum. CCL4 signiﬁcantly reduced the level of Super Oxide Desmutase (SOD), which is associated with increase
in lipid peroxidation. Treatment of animals with
asafoetida extracts signiﬁcantly elevated the
level of SOD and reduced the lipid peroxidation
[31]. Increase in liver enzymes by CCL4 is
associated with liver damages. The strong antioxidant activity of SOD and lowering the
oxidative stress in the liver play an important
role in liver protective effects of asafoetida gum
extract. Asafoetida and its sulﬁde components
exhibited the strong antioxidant activity against
produced free radicals [32], which restored the
activity of antioxidant enzymes, and liver enzymes and protected against the toxic effects of
CCL4 on liver.
The anti-diabetic effects of Asafoetida gum
water suspension (25, 50 mg/kg) were evaluated
against 10% fresh fructose treated rats for eight
weeks. The body weight, liver weight, abdominal fat, liver fat, leptin level and the histopathology of epididymis of rats were determined.
A signiﬁcant increase in fasting blood sugar
(FBS) (p < 0.05) and IPGT (intra-peritoneal
glucose tolerance Tests) (p < 0.01) was observed
in control group. Assessment the body weights
in different groups, every two weeks exhibited
that asafoetida gum water suspension signiﬁcantly reduced the body weights and abdominal
fats in comparison with control group. Asafoetida gum water suspension signiﬁcantly reduced
the dense of lipid droplets and the size of
abdominal adipocytes in histopathology smears
of treated rats (p < 0.05). The leptin level was
signiﬁcantly lower in asafoetida group than that
of control group [33]. Asafoetida inhibited the aglucosidase enzyme and reduced the glucose
absorption from digestive system and blood
glucose [34]. Hydrolysis of asafetida proteins by
gastric digestive enzymes enhanced the
reducing power activities of asafoetida gums
[35]. According to the results of this study [33],
asafoetida gum water suspension reduced the
body and liver fats in type 2 diabetic rats. High
level of leptin in serum was associated with the
fat deposition and increase in body weight.
Asafoetida water suspension signiﬁcantly
reduced the hepatosteatosis (Fatty liver disease)
in obese type 2 diabetic rats and showed antiobesity effects in rat animal model and protected the liver against hepatosteatosis by
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Table 2. The identiﬁed components responsible for biological activity in gastrointestinal tract.
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[49,78]
[66]
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[68]

Ferulic acid
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Vinyl disulﬁdes

reducing the serum leptin level. Asafoetida by
reduction of leptin level, the lipid droplets and the
size of abdominal adipocytes is suitable candidate
for obesity and other metabolic diseases related to
obesity.
2.2. F. asafoetida and functional dyspepsia
One of the most common diseases related to
gastrointestinal tract is functional dyspepsia, which
is associated with bloating, belching, heart burn,
indigestion, epigastric pain, early satiety and poor
quality of life.
In a double blinded placebo controlled randomized study, the efﬁcacy of asafoetida gum was evaluated on 48 patients with functional dyspepsia
(25e60 years old), who diagnosed by Rome III diagnostic criteria. The patients were randomly divided
in two groups of asafoetida and placebo groups and
the patients received 2 capsules of 250 mg asafoetida
or placebo for 30 days. The efﬁcacy of treatments,
adverse effects, hematological and pathological parameters was evaluated in two groups of treatments.
The individual dyspepsia symptoms, overall severity
scores were compared between two groups. In regard of Gastrointestinal Symptom Rating Scale

chemo protective effects

(GSRS), asafoetida capsule signiﬁcantly reduced the
overall severity score to 51.6% in comparison with
placebo and baseline. The Glasgow Dyspepsia
Severity Score (GDSS) signiﬁcantly reduced from
10.45 ± 0.21 to 4.80 ± 0.17; (p  0.001) in F. asafoetida
group and from 10.79 ± 0.20 to 9.22 ± 0.25; (p > 0.05)
in placebo group. A signiﬁcant improvement in
functional dyspepsia symptoms was reported in 69%
of patients in asafoetida group, and 87% of patients
in this group had no treatment with synthetic drugs.
Nepean Dyspepsia Index-Short Form (NDI-SF)
showed 38.67% reduction in overall symptoms in
asafoetida group, compared with placebo group. 81%
of the subjects had signiﬁcant reduction in clinical
symptoms of GSRS, GDSS, and NDI. Asafoetida
signiﬁcantly reduced bloating (58%), postprandial
fullness (74%), appetite (69%), motion sickness (75%),
and indigestion (77%). 66% of patients in asafoetida
group were symptom free. Asafoetida capsule had no
signiﬁcant effect on hemoglobin, RBC, PCV, MCV,
MCH, MCHC, liver and renal markers in comparison with placebo group [36]. The efﬁcacy of asafoetida in treatment of functional dyspepsia can be
related to its some biological activities such as its
anti-secretory, analgesic, anti-inﬂammatory, antioxidant and relaxant effects on gastro-intestinal effects.
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2.3. The anti-secretory and anti-ulcer effects of F.
asafoetida
The use of anti-secretory drugs in patients with
functional dyspepsia can reduce the clinical symptoms of disease [37].
The anti-secretory effects of intra-peritoneal injection of 250, 500 mg/kg body weight asafoetida
aqueous suspension were determined in Wistar albino rats by pylous ligated (Shay) test. The stomach
of animals was removed 6 hours after surgery and
the anti-secretory and anti-ulcer effects of asafoetida
water suspension were determined. The titration of
stomach content by NaOH exhibited that asafoetida
water suspension signiﬁcantly reduced basal gastric
secretion and completely inhibited the ulceration.
Asafoetida water suspension reduced the basal
gastric secretion from 8.83 ± 0.98 ml to 6.08 ± 0.15
(250 mg/kg) in control group and 4 ± 0.22 ml
(500 mg/kg) in asafoetida water suspension treated
group. The ulcer index in control group was
1.0 ± 0.36, while ulcer index was completely
inhibited in asafoetida water suspension. The pretreatment of mice with asafoetida water suspension,
30 minutes before oral administration of indomethacin (30 mg/kg b.w) in fasted rats, inhibited the
ulceration at the concentration of 500 mg/kg
(20.66 ± 4.05). Asafoetida aqueous extract (250 mg/
kg) reduced the ulcer index in indomethacin treated
rats (24.66 ± 4.05), but the difference was no significant with control group (34.66 ± 4.58). Pretreatment
of rats with asafoetida water suspension (250,
500 mg/kg) increased the gastric wall mucus from
351.30 ± 15.76, and 367.81 ± 11.14 to 327.07 ± 9.07,
and 464.31 ± 12.92 in control and ethanol treated
groups. Also, pretreatment of rats with asafoetida
water suspension in presence of necrotizing agent
signiﬁcantly reduced the stomach lesions. The
gastric mucosal NP-SH (non-protein sulfhydryl
groups in glandular stomachs of mice) was evaluated in ethanol (80%) treated fasted rats and F.
asafoetida water suspension groups. Ethanol (80%)
signiﬁcantly reduced the NP-SH in ethanol treated
rats (6.38 ± 0.33 mmol/100 mg), while pretreatment
of rats with asafoetida water suspension (250,
500 mg/kg) inhibited the depletion of NP-SH
(6.47 ± 0.36; 7.94 ± 0.80 mmol/100 mg). The NP-SH
concentration was 8.59 ± 0.33 mmol/100 mg in control group. Hemorrhage, ulceration, inﬂammation,
dysplastic and necrosis of gastric mucosa were
inhibited in ethanol treated animals. Congestion,
edema, and erosion were seen in F. asafoetida water
suspension group as ethanol treated group [20].
The anti-gastric ulcer effects of asafoetida aqueous
extract was evaluated in mice by oral single dose of

48 mg/kg indomethacin. The animals were divided
in four groups of control group (5 ml/kg saline solution), indomethacin group, and oral single dose of
25, 50 mg/kg asafoetida for 4 days. The lesions in
liver and stomach were determined in different
groups, and the ulcer index was determined by sum
of total length long ulcers and pectorial lesions, and
the maximum percent of curative ratio were recorded. Pretreatment of mice with asafoetida signiﬁcantly reduced the ulcer index, which was
associated with microscopic and macroscopic curative ratio in comparison with indomethacin group.
The ulcer healing process was dose dependent. The
percent of microscopic ulcer protections were 80.3%
and 89.2% in different doses of 25 and 50 mg/kg
asafoetida groups, while the corresponding macroscopic protections were 59.1% and 73.5% in asafoetida groups. The macroscopic and microscopic ulcer
indexes were 13.2, and 11 in indomethacin treated
group, while the microscopic ulcer indexes reduced
to 3.2 and 2.1 in asafoetida groups. Histopathology
of gastric mucosa in control group had normal
structure, while deep damages in mucosal structures and gastric glands were observed in indomethacin group. A mild discontinuity of mucosal
layers and local edema in stomach gland were seen
in low dose of asafoetida group, the structure of
mucosal layers with less disruption and edema and
ulcer were seen in this group. The results of histopathology experiments showed the cytoprotective
effects of asafoetida extract in a dose dependent
manner. Asafoetida aqueous extract reduced the
inﬂammation around the central vein, and it dilated
the hepatic sinusoids, and expanded the vessel in
portal area [38]. Asafoetida water suspension
signiﬁcantly inhibited the basal gastric acid secretion and ulceration in pylorus ligated rat animal
model and showed inhibitory effects against indomethacin induced mucosal injury or injuries by
other necrotizing agents. Asafoetida water suspension signiﬁcantly increased the gastric wall mucus in
rats. The presence of ﬂavonoid glycosides, ferulic
acid and coumarins in asafoetida water suspension
[39] as antioxidant compounds and membrane stabilizing agent scavenge the free radicals in membranes [40e42]. The antioxidant activity asafoetida
plays an important role in anti-ulcer effects of
asafoetida gum. The strong cell defense of asafoetida gum protect the cell membrane, which may
involve in its anti-ulcer effects [43]. The noncompetitive antagonistic effects of asafoetida on
muscarinic receptors could be one of proposed
mechanism(s) of action [44]. Galbanic acid blocks
the farnesyl transferase. Farnesyl transferase, as
critical enzyme activates the oncogene process in
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the body [4]. Therefore, the anti-secretory effects of
asafoetida and its inhibitory effects on ulceration
and mucosal injuries help the patients with functional dyspepsia.
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Pain is one feature of gastrointestinal diseases like
functional dyspepsia and IBS. The analgesic effects
of asafoetida have been conﬁrmed in different
studies. The anti-nociceptive effects of asafoetida
gum aqueous extract (2.5, 5, 10, and 20 mg/kg) was
evaluated in hot plate test and acetic acid writhing
test in male albino mice. For evaluation of some
possible mechanisms related to its anti-nociceptive
effects, naloxone (5 mg/kg), theophylline (5 mg/kg),
yohimbine (5 mg/kg), methylsergide (5 mg/kg),
haloperidol (1 mg/kg), and glibenclamide (2 mg/kg)
were applied 30 minutes before intra-peritoneal
administration of 10 mg/kg asafoetida. The carrageenan induced edema inhibition was evaluated by
intra-peritoneal administration of asafoetida, 15 minutes before injection of carrageenan. The soybean
15-lipoxygenase assay was used and lipoxygenase
inhibition and the antioxidant activity were determined by DPPH assay. In hot plate test, the
maximum analgesic effects were observed 15 minutes after injection of 10 mg/kg asafoetida. In acetic
acid writhing test, the effect of 10 mg/kg asafoetida
was signiﬁcantly lower than control group. The antinociceptive effects of asafoetida were not reversed
by naloxone, glibenclamide, theophylline, yohimbine, methysergide, and haloperidol. Asafoetida
(2.5 mg/kg) had signiﬁcant anti-inﬂammatory effects
in carrageenan induced mice paw edema. Asafoetida gum extract inhibited the lipooxygenase and
had antioxidant activity. The analgesic effects of
10 mg/kg asafoetida aqueous extract was higher
than 8 mg/kg morphine sulfate in hot plate test and
acetic acid induced writhing test [45]. It seems that
the anti-nociceptive effects of asafoetida gum extract
was not mediated by the receptor antagonizing
agents such as naloxone and other antagonists, and
the inhibition of lipooxygenes/cyclooxygenase in
arachidonic cascade implied on its central and peripheral analgesic effects. The analgesic effects of
asafoetida are attributed to ferulin. The anti-inﬂammatory effects of asafoetida can be related to
umbelloprenin, ferulc acid, fetidones A, B with
inhibitory effects against lipoxygenase [46].

(delayed gastric emptying) needs the prokinetics to
accelerate the gastric stasis.
Asafoetida (400 mg/kg) inhibited the intestinal
propulsion and reduced the propulsive action of
intestine in mice and exhibited the spasmolytic effects [47]. The antispasmodic and spasmolytic actions of asafoetida aqueous extract and essential oils
(0.1, 0.2, and 0.3%) were evaluated on segments of
ileum for 20 minutes. The contractile response of
each treatment was induced by 1012 e 102
acetylcholine. The spasmolytic evaluations were
determined by treatment of tissue with 104 acetyl
choline for 5 minutes, and then the maximum contractions were determined. The antispasmodic effects of asafoetida oil were stronger than its gum
aqueous extract. Asafoetida (0.2% and 0.3%)
reduced the maximum contraction induced by 104
acetyl choline by 12% and 43% [48]. The amount of
sulfur compounds in asafoetida oleo-gum resin was
higher than its essential oil. The relaxant effects of
asafoetida on isolated ileum was dose dependent,
while the amounts of sesquiterpene hydrocarbons,
monoterpene hydrocarbons, and oxygenated sesquiterpenes were higher in asafetida seed essential
oil [48].
Asafoetida can inhibit the histamine induced
smooth muscle contractions of gastrointestinal tract
[49]. There are different mechanisms are supposed
to be related to the relaxant effects of asafoetida
gum extracts. Asafoetida gum extract nonspeciﬁcally reduces the cytosolic Ca2þ, which has access to
the cytoplasm through L- type voltage operated
channels. The vasodilatory effects of asafoetida
essential oil is mediated by activation of potassium
channels, inhibition of calcium channels and intracellular calcium mobilization [50]. Rather than its
calcium channel blocking effects, the inhibitory effects of asafoetida extract on muscle's M3 subtype
muscarinic receptors or its histaminic antagonistic
activities, or stimulatory effects on b-adrenergic receptors are other related mechanisms of action in
relaxant effects of asafoetida on smooth muscle [51].
Asafoetida inhibits the muscarinic and histaminic
(H1) receptors or activates the adrenergic receptors
on calcium channels [44,51e53]. The relaxant effects
of asafoetida extract is attributed to pinenes [54,55],
thymol and their competitive effects on muscarinic
receptors in presence of atropine [44,53]. Atropine in
presence of F. asafoetida has more inhibitory effects
on smooth muscles.

2.5. Relaxant effects of F. asafoetida

2.6. Anti-diarrhea effect of F. asafoetida

Muscle relaxants can improve the gastric accommodation in functional dyspepsia, but Gastroparesis

Diarrhea can be a clinical sign of some gastrointestinal diseases, which is associated with loose,

2.4. The analgesic effects of F. asafoetida
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watery stools, abdominal cramps, pain, and
bloating.
The antidiarrheal effect of asafoetida ethanol
extract (90%) was evaluated in Wistar adult male
rats. The LD50 of asafoetida ethanol extract was
determined at doses of 10, 100, 1000, 1600, 2900,
5000 mg/kg for 14 days. The LD50 was determined
and 0.1 of LD50 was used as therapeutic dose. In this
experimental study, rats were randomly allocated
into negative control (Normal Saline), positive control (0.1 mg/kg atropine) and interventional groups
(100, 200, 400 mg/kg). 1.5 hours after treatment of
groups, the animal received the oral active charcoal
(1.5 ml e 10%) plus 5% tragacanth and the time of
intestinal passage of materials was determined.
Atropine as anti-cholinergic drug signiﬁcantly
reduced the intestine movements (p < 0.05). The
path of material in intestine insigniﬁcantly was
higher in 400 mg/kg asafoetida group than that of
control group. 100 and 200 mg/kg asafoetida
signiﬁcantly reduced the movement of intestinal
materials, and the low doses of asafoetida had
higher effects on intestinal transit. Among different
doses of asafoetida, only 100 mg/kg asafoetida
signiﬁcantly inhibited the transit of materials
(p < 0.05). Progression of gastrointestinal passage
was 89.16 ± 3.45 cm in control group, while in
atropine group (0.1 mg/kg) was 52.86 ± 7.24 cm. The
progressions of gastrointestinal passage were
97 ± 1.15, 65.88 ± 8.69, and 62.23 ± 0.67 cm for 400,
200, and 100 mg/kg asafoetida extract, respectively.
The use of 0.1 mg/kg atropine, and 100 mg/kg
asafoetida reduced the progression of gastrointestinal passage to 46.45 ± 2.42 cm. 100 mg/kg asafoetida extract had no signiﬁcant difference with
atropine in progression of gastrointestinal passage
(p < 0.05).
The effect of asafoetida (100, 200, 400 mg/kg) was
compared with lopramide (3 mg/kg) on castor oil
induced diarrhea in rats. One hour after treatments, all animals received 2 ml castor oil and each
rat was kept in cages, separately. The variables
were including the time of starting the diarrhea,
diarrhea scores, the number of stools, the stool
weights during 4 hours. Lopramide inhibited the
diarrhea during four hours. In asafoetida group,
the time for start of diarrhea insigniﬁcantly
increased by increase in dose of asafoetida. The
diarrhea score and changes in stool weight significantly reduced in asafetida (400 mg/kg) in comparison with control group (p < 0.05), although an
insigniﬁcant reduction in stool weight was
observed in other groups.
For evaluating the effects of asafetida hydroalcoholic extract on liquid accumulations in

experimental diarrhea model, all animals received
the castor oil and active charcoals, 0.5 hours after
that, the small intestine length, and the whole way
by active charcoal, and the secreted liquids into intestines were evaluated. Assessing the amount of
accumulated liquid in intestine after induction of
diarrhea showed that asafoetida gum reduced the
secretion and accumulation of liquids in intestine,
but these reductions were insigniﬁcant. Lopramide
signiﬁcantly inhibited the progression of intestinal
materials, while asafoetida gum insigniﬁcantly
reduced the intestine movement [56]. The results of
this study showed asafoetida ethanol extract at low
doses (100 mg/kg) had inhibitory effects on transit of
intestinal materials, which is in agreement with researchers who reported its spasmolytic effects on
guinea pig ileum [49,57] and high doses of asafoetida signiﬁcantly increased the intestinal movement,
which it makes suitable for constipation, paralysis,
reduced intestinal movement after surgery.
2.7. Anti-parasite effects of F. asafoetida
Asafoetida is traditionally used for its anti-helminthics properties in Iran, China and Nepal [58].
Blastocystis hominis is the most common intestinal
parasite in human, which infects 10% of people in
developed countries, and 50e60% in developing
countries. Clotrimazole is recommended for treatment of this parasite, but its application is associated
with adverse effects. Asafoetida essential oil
decreased the count of different isolates of Blastocystis sp. Subtype 3, in a dose and time dependent
manner. Asafoetida powder and its essential oil had
different inhibitory effects on Blastocystis sp. Subtype 3. Asafoetida powder and essential oil caused
irreversible damages on Blastocystis sp. Asafoetida
powder (16 and 20 mg/ml) had the maximum
inhibitory effects on Blastocystis sp. with inhibition
percent of 97.3e100%. Asafoetida essential oil (40,
50 mg/ml) had the highest percentage inhibition
about 84e100%, and 100%, respectively. Blastocystis
morphology had detrimental changes in presence of
higher concentrations of Blastocystis sp., and viable
vacuolar forms were replaced by granular forms
with shriveled appearance. So, the disintegrated
parasites, and cell debris were seen under the microscope observations. The minimal inhibitory
concentration (MIC) of asafoetida powder and oil
were 16 and 40 mg/ml, respectively, and these MIC
values killed the Blastocystis sp. after 72 and
144 hours, respectively. Clotrimazole at the concentration of 10, 100, and 500 mg/ml completely
inhibited the growth of Blastocystis sp. in vitro condition [59].
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The anti-helminthics effect of asafoetida aqueous
extract (25, 50, 100 mg/ml) was evaluated against
Pheretima postuma was compared with Piperazine
citrate. The paralysis time for P. postuma (min) at
concentrations of 25, 50, 100 mg/ml asafoetida
aqueous extract were 24 ± 0.14, 17 ± 0.13, and 6 ± 0.1
and the time for death at these concentrations were
56 ± 0.17, 39 ± 0.15, and 18 ± 0.04 min. Piperazine
citrate (25, 50, and 100 mg/ml) lysed the P. postuma at
22 ± 0.08, 15 ± 0.15, and 8.0 ± 0.06 min, the corresponding time for death were 52 ± 0.13, 37 ± 0.18,
and 20 ± 0.02 min. So, asafoetida aqueous extract
(100 mg/ml) had the best effect on killing the worm.
The anti-helminthic effect of asafoetida gum aqueous
extract was higher than piperazine citrate [60].
Strongylus spp. is an important nematode parasite
of horses and related equidae. 1 ml asafoetida aerial
parts ethanol extract (100, 50, 10, mg/ml) were
treated with 1 ml of Strongylus spp. larval suspensions and the survival rates of larvae were determined 1, 2, 3, 24, and 48 hours after incubation at
25  C. The hydro alcoholic extract of asafoetida killed over than 90% of the larvae on the ﬁrst day of
incubation. 50 and 100 mg/ml asafoetida extract
killed 100% larvae after 48 hours incubation [61].
The results of anti-parasite effects of asafoetida
have been conﬁrmed in experimental studies, and
require its evaluation in pharmacological and
human studies.
2.8. F. asafoetida and cancer
Gastrointestinal cancers are a group of cancers in
esophagus, stomach, pancreas, colon, rectum,
biliary system, liver, and small intestines. The indication of F. asafoetida in European countries is
abdomen, and liver cancers [1].
The cytotoxic effects of asafoetida essential oil on
human liver carcinoma cell lines (HCC) by MTT
assay were in a dose dependent manner. The IC50
for essential oil were 7.21 ± 0.29 mg/ml and
8.0 ± 0.36 mg/ml for HepG2 and SK-Hep1, respectively. Treatment of cell lines with essential oil
reduced the NFKB1 and TGFB1 and increased the
CASP3 and TNF [62]. NF-kB plays essential role in
development, cell growth, proliferation of cells in
pathological conditions such as metastases [63]. The
increase in CASP3 and TNF-a imply on inducing
the pro-apoptotic process through different pathways, and controlling the carcinogenesis [64].
The efﬁcacy of asafoetida (50, 100, 200 mg/kg) was
evaluated in 1,2-dimethylhydrazine (DMH) induced
colon cancer in Sprague Dawley rats. The animals
were divided in 6 groups of 1-vehicle group (subcutaneous 1 mM Ethylene diamine tetraacetic acid

59

(EDTA) saline, every week), 2e30 mg/kg DMH
dissolved in 1 mM EDTA every week, 3e5, oral
pretreatment of animals with 50, 100, 200 g/kg body
weight and weakly DMH injections, 6- pretreatment
of animals with 200 mg/kg asafoetida aqueous
extract. The animals were treated for 16 weeks. The
body weight, colon tumor, and total sialic acid were
determined in different groups. The gross
morphology of histopathology samples was determined under light microscope. After 16 weeks of
treatment, the body weight changes were determined, and the results exhibited that DMH administration for 16 weeks signiﬁcantly reduced the body
weight from 279.16 ± 16.25 to 221.5 ± 14.74 g. Coadministration of asafoetida aqueous extract in
DMH treated animals increased the body weight in
comparison with DMH group and improved the
overall body metabolism. The tumor incidence was
100% in DMH group, while the incidence of tumor
reduced to 66.6%, 50%, and 50% in 50, 100, 200 mg/
kg asafoetida treated animals. The incidence of
tumor (%) was zero at control and asafoetida group.
The mean of tumor multiplicity per animals was 2.5
in DMH group, followed by 50 (1.33), 100 (1.0), and
200 (1.17) mg/kg asafoetida, respectively. The tumor
size (cm) was 0.88 ± 0.01 in DMH group and
reduced to 0.75 ± 0.04 and 0.66 ± 0.12 cm in 5 and
100 mg asafoetida groups. 200 mg/kg asafoetida
reduced the tumor size in DMH treated group to
0.71 ± 0.07 cm. DMH signiﬁcantly increased the
thiol-speciﬁc antioxidant (TSA) levels in serum of
rats from 29.66 ± 2.29 mg/dl in control group to
53.41 ± 3.46 mg/dl in DMH group. The TSA levels
were 44.38 ± 1.29, 39.44 ± 4.74, and 41.16 ± 3.96 mg/
dl in different concentrations of asafoetida groups.
The amount of TSA was 32.19 ± 2.49 in 200 mg/kg
asafoetida group alone. Histopathology samples of
different groups exhibited the normal colonic
structure, while in DMH; the abnormal colon had
irregular glands. An improvement in irregular
mucosal lining in architecture of colon was observed
in asafoetida treated animals. The lower focal inﬂammations were observed in asafoetida treated
animals. The improvement in colon architecture
was better in higher concentration of asafoetida
(100 mg/kg), in comparison with 50, and 200 mg/kg
asafoetida aqueous extract [65]. The chemo protective effects of asafoetida were conﬁrmed against
colon cancer in DMH treated animals. The tumor
incidence, tumor size, and colon architecture and
the total sialic acid level improved in presence of
asafoetida gum. During the carcinogenesis, the total
sialic acid increased in serum as the result of cellular
proliferation. The mechanism responsible for
chemo-preventive effects of asafoetida may be

60

BULLETIN OF FACULTY OF PHARMACY, CAIRO UNIVERSITY 2022;59:50e63

Fig. 2. The efﬁcacy of asafetida gum in treatment of gastrointestinal disorders.

related to the presence of antioxidant components
such as ferulic acid with anticancer effects against
breast and colon cancer [66]. Galbanic acid induced
the apoptosis in cancerous cell lines by activation of
caspase and inhibition of Mcl-1 [67]. Vinyl disulﬁdes
from asafoetida activated the TRPA1 [68]. Oral
administration of asafoetida increased the life span
in mice animal model [69]. Different mechanisms
provide a mechanistic basis for potential beneﬁcial
health claims associated to the use of asafoetida.
2.9. Safety and dose of F. asafoetida
The LD50 of asafoetida aqueous extract was 1600 mg/
kg in mice [3]. Evaluation of asafoetida (12.5, 25, 50 and
100 mg/kg) for 30 days on hepatic (AST, ALT, ALP),
renal (Urea, Cr), cardiac (CPK) and blood biochemical
parameters (Pt, Ptt) of male Wistar rats showed pretreatment of animals with asafoetida signiﬁcantly
reduced the plasma level of AST, CPK and Ptt
(P < 0.05). High doses of asafoetida reduced the
plasma urea concentration and increased the plasma
Cr concentration and blood pressures. The low dose of
asafoetida (25 mg/kg) is a safe dose without any side
effects [70]. The results of acute toxicity test of
asafoetida water suspension exhibited that 100 mg/kg
asafoetida was safe without toxicity effects [33].
Asafoetida is abortifacient, its use is not recommended during pregnancy and lactation. The fatal
hemoglobin is oxidized by asafoetida, while
asafoetida had no effect on adult hemoglobin [1].
The oral use of asafoetida gum resin in infants lower

than 4 months are associated with risk of methemoglobinemia due to deﬁciency in glucose-6-phosphate dehydrogenase [71]. There is one report on
reduction of blood hemoglobin in 5 months child,
who received undeﬁned dose of asafetida resin [72].
The allergic and skin sensitivity is reported in people with allergic to Umbelliferae family. The activity
of warfarin is enhanced by asafoetida [73] and
asafoetida has deleterious effects on sister chromatids of sperm and spermatocytes [74].
Different concentrations of asafoetida (10, 50, 100,
250, 2000, 5000 mg/g) orally for 32 days (four cycles of
spermatogenesis) was administrated in non-inbred
male Swiss A mice. No aberrations were observed at
concentration of 50 mg, but the break and translocations increased in a dose dependent manner
and the minimum dose of asafoetida to mouse
translocate is 0.8 g. Low concentration of 7-hydroxycoumarin in asafoetida can be mutagenic for
mammalian chromosomes. Although, 15 g asafoetida had no mutagenic effect on cultured human
leucocytes, asafoetida treated male mice with female
mice for 15 days had not given rise to a pregnancy.
Totally, asafoetida caused structural chromosal aberrations in primary spermatocytes of mice and with
increase in asafoetida concentrations; the frequency
of chromosomal aberrations was not linear, and a
few abnormalities were seen in spontaneous
polypoid cells [75]. Oral administration of asafoetida
(0.5 and 1 g/kg body weight) induced a weak sister
chromatid exchange in spermatogonia [74]. Wheat
ﬂour, other cheap oleo-gum resin, and small stone
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particles are adulterations in asafoetida gum [76].
Oral asafoetida extract (5 g/kg) had no toxic effect in
rats [56].
0.3e1 g asafoetida resin 3  /day or 2e4 ml
asafoetida tincture, or 20 drops of tincture are recommended doses. The dose of resin is not determined correctly, but in India, 200e300 mg asafoetida
resin is used for treatment of kidney and gall stones
[77].

3. Conclusion
Asafoetida gum is used in different traditional
systems for treatment of gastrointestinal diseases.
Asafoetida gum is used for treatment of dyspepsia,
worm, cancers, and many other diseases according
to its traditional belief. In modern medicine, the
efﬁcacy of asafoetida gum aqueous extract was the
subject of experimental studies. The garlic odor of
asafoetida is secreted from breath, and gastric secretions. According to Chinese believes, asafoetida
resin can enter into the liver, spleen and the channels of stomach and stimulate them [23].
The liver protective effects of asafoetida against
the toxic effects of arsenic and CCL4 were
conﬁrmed in animal studies. There is one clinical
study on efﬁcacy of asafoetida gum aqueous
extract in functional dyspepsia, and it seems that
the analgesic, anti-inﬂammatory, anti-ulcer and
anti-secretory effects of asafoetida gum play an
important role in its efﬁcacy in functional
dyspepsia. The anti-diarrheal, anti-parasite and
anti-cancer effects of asafoetida have been limited
to experimental studies (Fig. 2) and required more
investigations. Although, asafoetida is safe in lower
doses, but take care about the correct dose should
be considered in human and animal studies. The
stinky odor of asafetida is other subject that should
be considered in formulations.
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